7 completed, 2 unknown, 1 recruiting, 1 terminated. 12 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 7, Unknown 2, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 4 | Unknown 2, Completed 1, Terminated 1 |
Follow Chronic Cough: new trials by email Literature Review of Chronic Cough trials Research Report on Chronic Cough
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation Prototypes Camlipixant - Cough | Phase 1 | Withdrawn | GlaxoSmithKline | 2026-07-02 | 2026-08-31 | |
| The Safety, Feasibility, and Repeatability of Inhaled ATP Cough Challenges Adenosine 5'-triphosphate - Chronic Cough (CC), Asthma | Phase 1 | Recruiting | McMaster University | 33 | 2025-08-05 | 2025-08-29 |
| A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough TCR1672 tablet - Refractory Chronic Cough | Phase 1 / Phase 2 | Unknown | Beijing Tide Pharmaceutical Co., Ltd | 72 | 2024-02-01 | 2024-01-19 |
| A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration HRS-2261 tablet、placebo - Chronic Cough | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 92 | 2022-03-28 | 2023-04-05 |
| Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175 3 mg NOC-100 (via nebulizer), 1 mg NOC-110 (via DPI) [1x 1 mg capsule], 3 mg NOC-110 (via DPI) - Refractory Chronic Cough | Phase 1 | Completed | Nocion Therapeutics | 24 | 2022-02-07 | 2023-03-30 |
| Cough Desensitization Therapy: Pilot 2 Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer, Saline - Cough | Phase 1 | Completed | University of Montana | 22 | 2021-05-01 | 2022-11-03 |
| Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants Rosuvastatin, Rosuvastatin + BAY1817080 - Drug Interactions | Phase 1 | Completed | Bayer | 14 | 2020-03-02 | 2021-03-11 |
| A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein BAY1817080 - Formulation A, BAY1817080 - Formulation B, [13C715N]-BAY 181708 stable isotope label (SIL) - Biological Availability | Phase 1 | Completed | Bayer | 30 | 2018-12-13 | 2019-08-19 |
| A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough GSK2798745, Placebo - Cough | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 17 | 2018-04-05 | 2019-10-02 |
| Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients BAY1817080, Matching Placebo - Cough | Phase 1 / Phase 2 | Completed | Bayer | 87 | 2017-12-07 | 2023-01-26 |
| Efficacy of Pregabalin on Chronic Cough Pregabalin, Control-Placebo - Cough | Phase 1 / Phase 2 | Unknown | Ottawa Hospital Research Institute | 40 | 2015-09-01 | 2020-09-25 |
| The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects GSK2339345 (solution), GSK2339345 (nebulised), Placebo (0.9% sodium chloride solution) - Cough | Phase 1 | Completed | GlaxoSmithKline | 31 | 2011-10-17 | 2017-06-20 |
Cough (6) · Asthma (1) · Endometriosis (1) · Pain (1) · cough hypersensitivity syndrome (1)
Pathological Conditions, Signs and Symptoms (12) · Respiration Disorders (12) · Respiratory Tract Diseases (12) · Signs and Symptoms (12) · Signs and Symptoms, Respiratory (12) · Cough (6) · Bronchial Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Lung Diseases (1)
Sodium Chloride (2) · Adenosine Triphosphate (1) · GSK2798745 (1) · Lidocaine (1) · Pregabalin (1) · Rosuvastatin Calcium (1) · Solutions (1)
Bayer (3) · GlaxoSmithKline (3) · Beijing Tide Pharmaceutical Co., Ltd (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · McMaster University (1) · Nocion Therapeutics (1) · Ottawa Hospital Research Institute (1) · University of Montana (1)
United Kingdom (4) · United States (3) · Canada (2) · China (1) · Netherlands (1)
Christopher Silber, MD (1) · Kayvan Amjadi, MD (1) · Laurie Slovarp, PhD (1)
PMID 33986030, PMID 35624408, PMID 36469250, PMID 37118696, PMID 38044419, PMID 38198010
2017 (2), 2018 (1)